
|Videos|July 19, 2017
Dr. Lara Discusses Epacadostat in Renal Cell Carcinoma
Author(s)Primo N. Lara, MD
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma.
Advertisement
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma (RCC).
Preliminary results from the phase II ECHO-202/KEYNOTE-037 trial showed encouraging response rates and safety signals with epacadostat plus pembrolizumab (Keytruda) in patients with metastatic RCC.
Lara says the advantages of a drug like epacadostat is that it is oral, so it provides an extra level of convenience, should it become a standard of care in the future.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































